Microbix Biosystems (TSX:MBX) Cyclically Adjusted Revenue per Share: C$0.15 (As of Mar. 2026)


TSX:MBX Microbix Biosystems Inc TSX:MBX
53 GF Score
Price C$0.32
GF Value C$0.25
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Microbix Biosystems Cyclically Adjusted Revenue per Share?

Microbix Biosystems TSX:MBX +6.67% 53 Cyclically Adjusted Revenue per Share is C$0.15 as of Mar. 2026. GuruFocus rates TSX:MBX with a GF Score™ of 53/100 and a GF Value™ of C$0.25 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Microbix Biosystems's adjusted revenue per share for the three months ended in Mar. 2026 was C$0.024. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$0.15 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Microbix Biosystems was 6.30% per year. The lowest was 0.00% per year. And the median was 2.50% per year.

As of today (2026-07-12), Microbix Biosystems's current stock price is C$0.32. Microbix Biosystems's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was C$0.15. Microbix Biosystems's Cyclically Adjusted PS Ratio of today is 2.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Microbix Biosystems was 6.46. The lowest was 1.35. And the median was 2.33.


Microbix Biosystems  (TSX:MBX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Microbix Biosystems's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.32/0.15
=2.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Microbix Biosystems was 6.46. The lowest was 1.35. And the median was 2.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Microbix Biosystems Cyclically Adjusted Revenue per Share Related Terms


Microbix Biosystems Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems Cyclically Adjusted Revenue per Share Chart

Microbix Biosystems Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.14 0.14 0.15 0.15

Microbix Biosystems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.15 0.15 0.15 0.15

TSX:MBX vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Microbix Biosystems's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's Cyclically Adjusted PS Ratio falls into.


TSX:MBX
53GF Score
Microbix Biosystems Inc TSX:MBX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbix Biosystems Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Microbix Biosystems's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.024/132.2623*132.2623
=0.024

Current CPI (Mar. 2026) = 132.2623.

Microbix Biosystems Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.027 102.002 0.035
201609 0.041 101.765 0.053
201612 0.023 101.449 0.030
201703 0.031 102.634 0.040
201706 0.033 103.029 0.042
201709 0.033 103.345 0.042
201712 0.030 103.345 0.038
201803 0.031 105.004 0.039
201806 0.033 105.557 0.041
201809 0.036 105.636 0.045
201812 0.025 105.399 0.031
201903 0.044 106.979 0.054
201906 0.032 107.690 0.039
201909 0.037 107.611 0.045
201912 0.021 107.769 0.026
202003 0.028 107.927 0.034
202006 0.027 108.401 0.033
202009 0.025 108.164 0.031
202012 0.029 108.559 0.035
202103 0.033 110.298 0.040
202106 0.037 111.720 0.044
202109 0.028 112.905 0.033
202112 0.034 113.774 0.040
202203 0.034 117.646 0.038
202206 0.035 120.806 0.038
202209 0.031 120.648 0.034
202212 0.018 120.964 0.020
202303 0.029 122.702 0.031
202306 0.040 124.203 0.043
202309 0.031 125.230 0.033
202312 0.062 125.072 0.066
202403 0.040 126.258 0.042
202406 0.037 127.522 0.038
202409 0.045 127.285 0.047
202412 0.045 127.364 0.047
202503 0.038 129.181 0.039
202506 0.025 129.892 0.025
202509 0.027 130.287 0.027
202512 0.030 130.366 0.030
202603 0.024 132.262 0.024

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of C$0.15 mean?
Microbix Biosystems (TSX:MBX) has a Cyclically Adjusted Revenue per Share of C$0.15 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Microbix Biosystems and its competitors.
Is Microbix Biosystems' Cyclically Adjusted Revenue per Share too high?
Microbix Biosystems' current Cyclically Adjusted Revenue per Share is C$0.15. Overall, Microbix Biosystems has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Microbix Biosystems' Cyclically Adjusted Revenue per Share of C$0.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current Cyclically Adjusted Revenue per Share is C$0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (TSX:MBX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.32 — trading 28% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is C$0.15. Microbix Biosystems' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Microbix Biosystems (TSX:MBX), the current Cyclically Adjusted Revenue per Share is C$0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (TSX:MBX) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of C$0.32 is trading 28% above its estimated GF Value™ of C$0.25. GuruFocus considers Microbix Biosystems to be Modestly Overvalued.

Key valuation signals for TSX:MBX:

  • Cyclically Adjusted Revenue per Share: C$0.15
  • GF Value™: C$0.25 vs. price of C$0.32 (28% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the TSX:MBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Microbix Biosystems Business Description

Other Exchanges MBXBF:USA
Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
53GF Score

Get the complete analysis for TSX:MBX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.32
Price
C$0.25
GF Value